Merck & Co., Inc. (NYSE: MRK) is one of the 14 Best Pharma Dividend Stocks to Buy in 2025. The company reported solid earnings in Q1 2025, with revenue of $15.5 billion, sales of KEYTRUDA rising by 4% to $7.2 billion, and WINREVAIR bringing in $280 million.

Merck (MRK) has a strong lineup of products in development and recent regulatory approvals for Winrevair and Enflonsia. The company has been rewarding shareholders with growing dividends for the past 14 years, offering a quarterly dividend of $0.81 per share with a 4.05% yield as of July 17.

Read more at Yahoo Finance: A Track Record of Consistency